EssilorLuxottica stock trades near yearly high as eyewear group grows revenue and profit

EssilorLuxottica stock is trading close to a yearly high on Euronext Paris as the Franco-Italian eyewear group (ISIN FR0000033219) continues to grow revenue and profit on the back of demand for prescription lenses and luxury frames. According to the companys latest full-year figures released on 8 February 2024, EssilorLuxottica generated around EUR 25.0 billion in revenue in 2023, marking solid top-line expansion compared with the prior year.

Revenue up around 7 percent

In its 2023 annual results, EssilorLuxottica reported that group revenue rose by roughly 7 percent versus 2022, reflecting both price and volume contributions in key regions such as North America, Europe, and Asia-Pacific. The eyewear specialist highlighted continuing demand for prescription lenses, optical frames, and sunglasses, with retail brands and wholesale partners supporting growth across channels.

Operating profitability improved alongside the revenue increase. EssilorLuxottica stated that adjusted operating profit climbed in 2023, with the margin expanding compared with the previous year thanks to mix effects and integration synergies. The company also signaled continued cost discipline, noting efficiency gains in manufacturing and logistics networks that helped offset inflationary pressures.

Net income and dividend grow

EssilorLuxottica reported that net income attributable to shareholders rose in 2023 compared with 2022, pointing to stronger earnings power after the consolidation of Essilor and Luxottica and subsequent integration efforts. The group emphasized that earnings growth was broad-based across segments, including the lens business and branded frames operations.

On capital returns, EssilorLuxottica announced a higher dividend for 2023 relative to the prior year, reinforcing its policy of sharing profit growth with shareholders. The increase in the dividend per share reflects the stronger net income and the companys confidence in its cash generation outlook. For investors, the combination of revenue expansion, earnings growth, and rising dividends underlines the fundamentals behind the share price performance.

Read more on EssilorLuxottica

For a deeper look at EssilorLuxottica, including historical earnings, balance-sheet metrics, and recent investor presentations, the Investor Relations site and structured data pages provide further detail on the companys strategy and financial profile.

Ray-Ban and lens portfolio

EssilorLuxottica generates a significant share of its revenue from well-known eyewear brands and lens technologies, with Ray-Ban standing out as one of its most recognizable global brands. The company has repeatedly indicated in its reporting that branded frames and sunglasses contribute meaningfully to sales and profitability, leveraging Ray-Ban and other licenses to drive consumer demand at retail and online.

On the lens side, EssilorLuxottica offers a broad range of ophthalmic lenses, including progressive designs and coatings marketed under various labels. These lenses are sold through optical chains, independent opticians, and healthcare networks, forming a core pillar of the group. The combination of proprietary lens technology and strong frame brands supports cross-selling opportunities and helps sustain margins.

EssilorLuxottica stock and market context

EssilorLuxottica stock is listed on Euronext Paris, and the company forms part of major French equity indexes, reflecting its sizeable market capitalization relative to the broader market. The shares have traded in a range that places the latest price near the upper end of the 52-week band, indicating that investors have rewarded the companys earnings progression and strategic positioning in eyewear and optical products.

Market observers point to EssilorLuxotticas diversified geographic footprint and balanced exposure to prescription eyewear, sunglasses, and retail operations as factors supporting the valuation. With revenue around EUR 25.0 billion in 2023 and net income up versus 2022, the companys scale and profitability make it a key player in the global consumer and healthcare space. For shareholders, the trajectory of margins, cash generation, and dividend policy will remain central to assessing EssilorLuxottica stock.